Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
71.17
-1.91 (-2.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
583,599
Open
72.61
Bid (Size)
70.50 (5)
Ask (Size)
72.00 (8)
Prev. Close
73.08
Today's Range
69.92 - 73.14
52wk Range
55.02 - 98.40
Shares Outstanding
47,190,970
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
April 16, 2024
Stocks that work for billionaires aren't necessarily appropriate for every investor.
Via
The Motley Fool
Performance
YTD
-7.64%
-7.64%
1 Month
-7.99%
-7.99%
3 Month
-20.50%
-20.50%
6 Month
+11.69%
+11.69%
1 Year
-2.93%
-2.93%
More News
Read More
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Analyst Ratings For Axsome Therapeutics
April 10, 2024
Via
Benzinga
2 Under-the-Radar Growth Stocks to Consider
April 10, 2024
Via
The Motley Fool
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
March 19, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Via
InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Via
Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
March 25, 2024
Via
Benzinga
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
Via
The Motley Fool
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Via
InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
February 26, 2024
Via
The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
February 20, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
February 20, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.